Obesity Management

From their originally intended purposes to the growing indications showing promise in development, GLP-1 and GIP receptor agonists have evolved rapidly.

Every pattern of hormonal contraceptive use was associated with subsequent semaglutide initiation, a signal pharmacists and prescribers should watch for.

Large trial emulation study finds a 21% reduction in 3-year fracture risk compared with DPP-4 inhibitors, independent of weight loss or glycemic changes.

Positive results from TRIUMPH-2 and TRIUMPH-3 bring retatrutide's obesity program to 5 successful trials, with Lilly planning to submit in early 2027.

A new report on glucagon-like peptide-1 receptor agonists for obesity finds real clinical value alongside budget impact that already exceeds the review's own threshold.

A secret shopper study finds most are still compounding semaglutide and tirzepatide with additives, often through suppliers lacking sterile compounding licenses.

With the Medicare GLP-1 Bridge Program just 2 weeks old, a drug market expert shared their thoughts on what the initiative may mean for pharmacists and their patients.

With GLP-1 questions creating confusion for Medicare patients, pharmacists are becoming the trusted frontline resource, and the stakes for getting it right have never been higher.

New research links a national surge in poison control calls involving semaglutide to preventable dosing mistakes rather than intentional misuse.

With the goal of optimizing long-term weight-loss treatment, researchers gather insights regarding the lived experiences of glucagon-like peptide-1 users.

A new analysis shows that socioeconomic status shrinks type 2 diabetes risk far more for nonHispanic white and Asian Americans than for nonHispanic Black and Hispanic Americans.

Through a secret shopper study, researchers assessed the process for obtaining GLP-1 therapy via the internet and the clinical engagement associated with the purchase.

Data show bone density and lean mass losses can be clinically meaningful, but case reports point to resistance training as effective countermeasures.

The filing acceptance marks a step toward lower-cost alternatives to Mounjaro and Zepbound.

Bryan Wheeler, PharmD, discusses how the Medicare GLP-1 Bridge program works and what it means for independent pharmacy operations.

The FDA approved Foundayo, which is an oral glucagon-like peptide-1 receptor agonist, for weight loss.

Despite the boom in prescription weight loss medications, the management of OTC alternatives is still paramount in improving patient outcomes and reducing adverse events.

Reports state that everyone from “shadowy online vendors” to physicians and nurses is illegally promoting the drug before it receives proper FDA approval.

Based on data from the ADA’s 2026 Scientific Sessions, glucagon-like peptide-1s are continuing to revolutionize the cardiometabolic disease landscape.

Once-weekly mazdutide drives approximately 17% weight loss in Chinese adults with obesity, offering a dual GLP-1/glucagon metabolic option.

Alabama bans research-grade peptides for patients amid FDA reviewing 12 peptides for compounding use.

New 9-year data shows some high-risk prediabetes patients progress to type 2 diabetes despite 8% weight loss.

Recent research data assessed the potential use of GLP-1s for reducing the progression of total knee arthroplasty.

Late-phase trials show switching to daily oral orforglipron or lower-dose tirzepatide helps maintain weight loss, easing regain and boosting adherence.

Results of Eli Lilly’s investigational triple agonist were reported in the TRIUMPH-1 Phase 3 clinical trial.